Hematologic Oncology | Specialty

Approaching First-Line Treatment Decisions in Pediatric ALL

January 30th 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss first-line treatment considerations for pediatric ALL.

Adding Blinatumomab to Consolidation Therapy in Older Patients With Newly Diagnosed, BCR::ABL1–Negative B-ALL

January 30th 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on blinatumomab as consolidation therapy in older patients with newly diagnosed ALL.

AlloHCT Outcomes From ECOG ACRIN E1910 in Newly Diagnosed, MRD-Negative B-Lineage ALL

January 30th 2025

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.

European Commission Approves Blinatumomab Consolidation in Newly Diagnosed CD19+ B-ALL

January 30th 2025

The European Commission has approved blinatumomab as consolidation therapy for Ph-negative, CD19-postive B-cell precursor acute lymphoblastic leukemia.

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

January 30th 2025

Dr. Elias K. Mai presents final progression-free survival results from the Phase 3 GMMG-HD7 trial, demonstrating that adding isatuximab to lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in transplant-eligible patients with newly diagnosed multiple myeloma.

Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies

January 29th 2025

CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.

Rapcabtagene Autoleucel May Be Safe and Efficacious in R/R DLBCL

January 28th 2025

Peter Riedell, MD, details the safety and efficacy of rapcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma.

Fixed-Duration Acalabrutinib plus Venetoclax With or Without Obinutuzumab versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

January 28th 2025

Dr. Alan Skarbnik discusses interim findings from the Phase 3 AMPLIFY trial, highlighting the efficacy and safety of fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, compared to chemoimmunotherapy for treatment-naive chronic lymphocytic leukemia.

Venetoclax/Pegcrisantaspase Combo Offers Potential to Overcome Venetoclax Resistance in R/R AML

January 27th 2025

Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

January 24th 2025

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR

January 23rd 2025

Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.

Highlighting Key CML/ALL Data Presented at ASH 2024

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.

Selecting a TKI in Subsequent Lines of Therapy in CML

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.

The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

Dosing Strategies for Ponatinib in CML and ALL

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.

Emerging Mutation Analysis from the OPTIC Trial

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma

January 22nd 2025

IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML

January 22nd 2025

Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.